Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 Cholangiocarcinoma

NCT07260175 | Recruiting Phase 2

• 4 other identifiers: adIVO2024-520219-42-00AIO-HEP-0125/ass.IKF-081
• Study Type: interventional
• Target: 40
• Locations: 1 country
• Sites: 8

Brief Summary

This study trial is a prospective, multicentre, exploratory, single-arm, open-label phase II study to evaluat ivosidenib maintenance after SOC adjuvant chemotherapy in curative mIDH1 cholangiocarcinoma

Conditions

Cholangiocarcinoma; IDH Mutation

Keywords

mIDH1 cholangiocarcinoma; ivosidenib maintenance; cholangiocarcinoma; R0-resection

Outcome Measures

Primary Outcomes (1)

• recurrence-free survival rate

  1-year recurrence-free survival rate (RFS@1year), defined as proportion of patients alive with no disease recurrence 1 year after start of maintenance ivosidenib

  1-year

Secondary Outcomes (7)

• recurrence-free survival

  at 66 months

• Time to recurrence

  after 66 months

• Time to treatment failure (TTF)

  at 66 months

• Overall survival

  at 66 months

• Safety (adverse events)

  at 66 months

Study Arms (1)

Ivosidenib maintenance

EXPERIMENTAL

Ivosidenib maintenance after SOC adjuvant chemotherapy in curative mIDH1 cholangiocarcinoma

Drug: Ivosidenib

Interventions

Ivosidenib DRUG

Ivosidenib (daily 500 mg) maintenance after SOC adjuvant chemotherapy in curative mIDH1 cholangiocarcinoma

Also known as: Ivosidenib Pill (daily 500 mg)

Ivosidenib maintenance

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patient\* provides signed informed consent.
• Patient is ≥ 18 years at the time of given informed consent.
• Patient has histologically documented curatively resected intrahepatic cholangiocarcinoma, without metastatic spread, in the adjuvant situation (R0-resected)
• Patient has proven IDH1 mutation (IDH1-variant status evaluated locally by certified test on formalin-fixed paraffin-embedded tumor tissue specimen. If local testing for screening is not possible per local standard, tumor tissue samples will be subject to pre-screening via central IDH1 dPCR)
• Patient has ECOG Performance status ≤ 1
• Hematological, hepatic and renal function parameters adequate to allow targeted therapy with ivosidenib at investigator´s discretion and IB.
• Patient has adequate coagulability to allow targeted therapy with ivosidenib at investigator´s discretion and IB. Patients receiving warfarin / Phenprocoumon must be switched to low molecular weight heparin and before starting trial-specific.
• Patient must be willingly to provide liquid biopsy samples, archival tumor tissue samples (if available), and in the event of disease recurrence, re-biopsy samples (if re-biopsy is considered safe for the patient) for the translational research program.
• Female patients of childbearing potential or male patients with female partners of childbearing potential must agree to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of \<1% per year during the treatment period and for at least 6 months after the last dose of trial treatment. Male patients with a pregnant partner must agree to remain abstinent or to use a condom for the duration of the pregnancy. Female patients of child-bearing potential must have a negative pregnancy test within the last 7 days prior to the start of trial therapy.
• Patient is willing and able to comply with the protocol (including contraceptive measures) for the duration of the trial including undergoing treatment and scheduled visits and examinations including follow up.

You may not qualify if:

• Patient has a metastatic or R+ resected biliary tract cancer.
• Patient received previous therapy with an IDH1 inhibitor.
• Patient has known presence of tumors other than intrahepatic cholangiocarcinoma or a secondary tumor other than squamous or basal cell carcinomas of the skin or in situ carcinomas of the cervix which have been effectively treated. The sponsor decides to include patients who have received curative treatment and have been disease-free for at least 5 years.
• Simultaneous, ongoing systemic immunotherapy, chemotherapy, or hormone therapy not described in the trial protocol.
• Patient receives simultaneous treatment with a different anti-cancer therapy other than that provided for in the trial (excluding palliative radiotherapy only for symptom control).
• Patient has a stage B cirrhosis according to Child-Pugh criteria (or worse) or cirrhosis (of any grade) with a history of hepatic encephalopathy or clinically significant ascites resulting from cirrhosis. Clinically significant ascites is defined as ascites resulting from cirrhosis requiring diuretics or paracentesis.
• Patient has known allergic / hypersensitive reactions to at least one of the treatment components.
• Patient has other serious illnesses or medical ailments within the last 12 months prior to the start of the trial.
• Patient has a known presence of an active, uncontrollable infection.
• Patient has QTc \> 480ms or other factors that, in the discretion of the investigator increase significantly the risk of QT prolongation or arrhythmic events (e.g. heart failure, hypokalemia, family history of long QT syndrome). NOTE: Medications that prolong the QT interval should be avoided, unless they can be transferred to other medication within ≥ 5 half-lives to dosing or unless the medications can be properly monitored during the study. (If equivalent medication is not available, QTc should be closely monitored).
• Patient has active disseminated intravascular coagulation.
• Patient has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
• Patient has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial drug.
• Patient has any other serious concomitant or medical condition that, in the opinion of the investigator, presents a high risk of complications to the patient or reduces the likelihood of clinical effect. NOTE: strong CYP3A4 inducers or sensitive CYP3A4 substrates with narrow therapeutic window should be avoided, unless they can be transferred to alternative medication within at least 5-half lives prior to dosing.
• Female patient is pregnant or breast feeding or planning to become pregnant within and 6 months after the end of treatment.

Sponsors & Collaborators

• Servier Deutschland GmbH: collaborator
• Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest: lead
• Servier Affaires Médicales: collaborator

Study Sites (8)

Uniklinik RWTH Aachen

Aachen, 52074, Germany

RECRUITING

Universitätsklinikum Bonn

Bonn, 53127, Germany

RECRUITING

Krankenhaus Nordwest

Frankfurt, 60488, Germany

RECRUITING

Universitätsklinikum Frankfurt

Frankfurt, 60590, Germany

RECRUITING

Universitätsmedizin Göttingen

Göttingen, 37099, Germany

RECRUITING

Uniklinikum Jena

Jena, 7747, Germany

RECRUITING

Universitätsklinikum Mannheim

Mannheim, 68167, Germany

RECRUITING

Klinikum rechts der Isar TU München

München, 81675, Germany

RECRUITING

MeSH Terms

Conditions

Cholangiocarcinoma

Interventions

ivosidenib

Condition Hierarchy (Ancestors)

Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms

Study Officials

• Salah Al-Batran, Prof. Dr.

  Frankfurter Institut für Klinische Krebsforschung IKF GmbH

  STUDY DIRECTOR

• Thorsten Götze, Prof. Dr.

  Krankenhaus Nordwest GmbH

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Thorsten Götze, Prof. Dr.

CONTACT

+49 69 76 01; Goetze.Thorsten@KHNW.DE

Johanna Riedel, Dr.

CONTACT

+49 69 5899 787; riedel.johanna@ikf-khnw.de

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 2, 2025
• First Posted: December 3, 2025
• Study Start: November 18, 2025
• Primary Completion (Estimated): December 1, 2030
• Study Completion (Estimated): December 1, 2031
• Last Updated: March 23, 2026

Record last verified: 2025-11

Data Sharing

• IPD Sharing: Will not share

Locations

DE (8)